Showing results (551-560 of 586) with videos related to
Sort By:
Pageof 59
Nature Communications|February 3, 2025
Early tolerance and late persistence as alternative drug responses in cancerSimona Punzi, Davide Cittaro, Guido Gatti, et al.Cancer Discovery|September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid TumorsTimothy A Yap, David S P Tan, Angelika Terbuch, et al.Nature|September 5, 2020
Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.Molecular Cancer Research : MCR|December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient OutcomesOmar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.Journal for Immunotherapy of Cancer|October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom InventoryTito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.Cancer Discovery|April 19, 2026
A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention and InterceptionMonte M Winslow, Mohamed A Ahmed, Christine D Berg, et al.JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic TrialAlison M Schram, Nicoletta Colombo, Edward Arrowsmith, et al.Nature|July 17, 2020
The National Lung Matrix Trial of personalized therapy in lung cancerGary Middleton, Peter Fletcher, Sanjay Popat, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2022
A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 ResistanceTimothy A Yap, Patricia M LoRusso, Deborah J Wong, et al.BMJ Oncology|January 31, 2025
Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancerChad Tang, Genevieve P Hartley, Coline Couillault, et al.Pageof 59